Acrivon Therapeutics, Inc. 10-Q filing
Filed 2026-05-13 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-221634
- Form type
- 10-Q
- CIK
- 0001781174
- Primary document
- https://www.sec.gov/Archives/edgar/data/1781174/000119312526221634/acrv-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Acrivon Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-19.9M | - | - |
| Net Income | $-19.0M | - | - |
| Eps Basic | -0.49 | - | - |
| Eps Diluted | -0.49 | - | - |
| Cash And Equivalents | $34.1M | - | - |
| Total Assets | $107.8M | - | - |
| Total Liabilities | $12.3M | - | - |
| Shareholders Equity | $95.5M | - | - |
| Operating Cash Flow | $-20.5M | - | - |
| Capital Expenditures | $14,000 | - | - |